Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425885 | PMC |
| http://dx.doi.org/10.12779/dnd.2018.17.4.174 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Drug Development.
Alzheimers Dement
December 2024
Theme Inflammation and Aging, Karolinska University Hospital, Stockholm, Sweden.
Background: Alzheimer disease (AD) is a progressive neurodegenerative disease that is accountable for the leading case of dementia in elder people. Before, only symptomatic treatments are available for AD. Since 2021, two anti-amyloid antibodies aducanumab and lecanemab have been approved by the US Food and Drug Administration.
View Article and Find Full Text PDFLecanemab, a humanized IgG1 monoclonal antibody that binds with high affinity to amyloid-beta (Aβ) protofibrils, was formally evaluated as a treatment for early Alzheimer's disease in a phase 2 study (Study 201) and the phase 3 Clarity AD study. These trials both included an 18-month, randomized study (core) and an open-label extension (OLE) phase where eligible participants received open-label lecanemab for up to 30 months to date. Clinical (CDR-SB, ADAS-Cog14, and ADCS-MCI-ADL), biomarker (PET, Aβ42/40 ratio, and ptau181) and safety outcomes were evaluated.
View Article and Find Full Text PDFDementia Care Research and Psychosocial Factors.
Alzheimers Dement
December 2024
University of Nairobi, Nairobi, Nairobi, Kenya.
Background: The recruitment of individuals for Alzheimer's disease (AD) genetic studies particularly those with low socioeconomic status, and living in rural areas remains a challenge in Sub-Saharan Africa (SSA), due to stigma-related cultural beliefs that hinder their participation. The Recruitment and Retention of Alzheimer's Disease Diversity Genetic Cohorts in the ADSP (READD - ADSP) project is a case-control genetic epidemiological study involving individuals who are living with AD and disease - free healthy control individuals. The aim is to build a resource that greatly expands Alzheimer's disease genetic studies in the currently underrepresented African ancestry populations and Hispanic/Latinx individuals.
View Article and Find Full Text PDFDementia Care Research and Psychosocial Factors.
Alzheimers Dement
December 2024
Weill Cornell Medicine, New York City, NY, USA.
Background: Early detection of Alzheimer's disease (AD) can improve prognosis, given new anti-amyloid therapies. Both positron emission tomography (PET) and magnetic resonance (MR) imaging biomarkers are currently used (1). 48F-Fluorodeoxyglucose-PET (FDG-PET) can detect neurodegeneration-related hypometabolism but is costly and not easily accessible (2).
View Article and Find Full Text PDFDementia Care Research and Psychosocial Factors.
Alzheimers Dement
December 2024
Erasmus University Rotterdam, Rotterdam, Netherlands.
Background: 'Intellectual assets' generated in traditional university settings, that may not fit the interests of the standard 'valuation criteria' (i.e. commercially profitable), such as non-pharmacological dementia care research, often remain siloed within their respective research disciplines and originating institutions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!